Bharat Biotech to make variant-specific shots of first nasal Covid-19 vaccine https://ift.tt/bkSgsOx

With iNCOVACC becoming the world's first intranasal Covid-19 vaccine to receive emergency use authorisation (EUA) as a primary vaccine as well as a heterologous booster for those aged 18 years and above, Bharat Biotech is now working on developing variant-specific versions of the vaccine.

from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/BZUhomN